Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696474 | 0.83 | LIPG (0.41) | LPLLIPGF11 | |
| SCHEMBL14696743 | 0.82 | LPL (0.40) | LPLLIPGF11 | |
| SCHEMBL9977366 | 0.82 | LPL (0.33) | LPLLIPG | |
| SCHEMBL15450937 | 0.81 | LIPG (0.40) | LPLLIPGP2RX7MAPK1F11 | |
| SCHEMBL16472113 | 0.81 | LPL (0.44) | LPLLIPG | |
| SCHEMBL18224239 | 0.81 | LPL (0.33) | LPLLIPG | |
| SCHEMBL2586990 | 0.79 | LPL (0.42) | LPLLIPGP2RX7F11 | |
| SCHEMBL30393353 | 0.79 | LPL (0.42) | LPLLIPGP2RX7F11 | |
| SCHEMBL20509733 | 0.77 | ESR2 (0.33) | LPLLIPG | |
| SCHEMBL837379 | 0.77 | LIPE (0.34) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962670-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962670-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8637490-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637490-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130045949-A1 | ANTI-CANCER AGENTS | UWM RESEARCH FOUNDATION, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045949-A1 | ANTI-CANCER AGENTS | UWM RESEARCH FOUNDATION, INC. (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045949-A1 | ANTI-CANCER AGENTS | TP53, MCL1, HRAS | LPL 1623/4885LIPG 344/4885P2RX7 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.